Grifols is set to vote on a shareholder meeting proposal that includes a new incentive plan valued at up to 9.3 million euros, which notably excludes Abia. The investment fund Mason Capital has aligned itself with Grifols' board, endorsing the proposed agenda and the list of appointments. Minority shareholders have expressed admiration for Grifols' international business, describing it as "suculento y envidiado" (attractive and enviable). Additionally, the acceptance period for Grifols' takeover bid (OPA) to exclude Biotest has been extended until June 6. Grifols is also focusing on expanding its presence in Egypt, one of its strategic markets, as outlined in its strategic plan presented in late February.
Grifols busca reforzar su presencia en Egipto, uno de sus mercados estratégicos, contemplado en el plan estratégico presentado por la compañía a final de febrero. #Industria #farmacéutica @SantiagoMillanA https://t.co/dyqMYpu7Hz
El fondo Mason Capital respalda la lista de nombramientos propuesta por Grifols https://t.co/QK0XGfOL2V
#LoMásLeído Mason Capital se alinea con el consejo de Grifols y respalda su propuesta para la junta de accionistas https://t.co/8AVg4t1GaI